Safety study of VS-041 for heart failure with preserved pumping strength
Part of Heart & circulation clinical trials.
This trial tests an investigational drug called VS-041 to see if it's safe and helps people with a type of heart failure where the heart pumps well but doesn't relax properly (HFpEF). It may be an option if you are 50 or older and have stable heart failure symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years of age or older.
- You have been diagnosed with heart failure with preserved ejection fraction (HFpEF).
- Your heart failure causes mild to moderate symptoms (NYHA class II or III).
- Your heart's pumping function is 50% or higher on an echo.
- Your NT-proBNP level is elevated (a sign of heart strain).
- You weigh at least 110 lbs (50 kg) and your BMI is between 18 and 45.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This trial studies people who have heart failure symptoms but whose heart pumping strength is largely preserved. It aims to better understand this specific type of heart failure and how best to treat or evaluate it.
This study looks at people with a type of heart failure where the heart pumps normally but still doesn't fill properly. Researchers are using ultrasound pictures of the heart (echocardiograms) and blood tests to better understand this condition and find better ways to treat it.
This study compares three different combinations of medicines to see which one works best for people with heart failure and a preserved ejection fraction (a type of heart failure where the heart's pumping function is normal but it doesn't fill properly). Participants will receive one of three treatments: vicadrostat plus empagliflozin, empagliflozin alone, or empagliflozin plus spironolactone. The study looks at how these medicines affect proteins in the blood, which may help doctors understand which treatment is more effective.
This study looks at whether fat around the heart affects a type of heart failure where the heart pumps well but is stiff (HFpEF). You may be able to join if you have this condition, are 18 or older, and can understand English.
This study tests an investigational medication called elecoglipron to see if it can improve heart and blood vessel outcomes in people with heart failure with preserved or mildly reduced ejection fraction. If you join, you will receive either the study drug or a placebo, and your heart health will be monitored over time.
Hear when a new Heart trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.